

RESEARCH

Open Access

In vitro anti-plasmodial activity of *Dicoma anomala* subsp. *gerrardii* (Asteraceae): identification of its main active constituent, structure-activity relationship studies and gene expression profiling

John VW Becker^{1,6}, Marina M van der Merwe^{1,2}, Anna C van Brummelen¹, Pamisha Pillay¹, Bridget G Crampton³, Edwin M Mmutlane¹, Chris Parkinson¹, Fanie R van Heerden², Neil R Crouch⁴, Peter J Smith⁵, Dalu T Mancama^{1*} and Vinesh J Maharaj¹

Abstract

Background: Anti-malarial drug resistance threatens to undermine efforts to eliminate this deadly disease. The resulting omnipresent requirement for drugs with novel modes of action prompted a national consortium initiative to discover new anti-plasmodial agents from South African medicinal plants. One of the plants selected for investigation was *Dicoma anomala* subsp. *gerrardii*, based on its ethnomedicinal profile.

Methods: Standard phytochemical analysis techniques, including solvent-solvent extraction, thin-layer- and column chromatography, were used to isolate the main active constituent of *Dicoma anomala* subsp. *gerrardii*. The crystallized pure compound was identified using nuclear magnetic resonance spectroscopy, mass spectrometry and X-ray crystallography. The compound was tested *in vitro* on *Plasmodium falciparum* cultures using the parasite lactate dehydrogenase (pLDH) assay and was found to have anti-malarial activity. To determine the functional groups responsible for the activity, a small collection of synthetic analogues was generated - the aim being to vary features proposed as likely to be related to the anti-malarial activity and to quantify the effect of the modifications *in vitro* using the pLDH assay. The effects of the pure compound on the *P. falciparum* transcriptome were subsequently investigated by treating ring-stage parasites (alongside untreated controls), followed by oligonucleotide microarray- and data analysis.

Results: The main active constituent was identified as dehydrobrachylaenolide, a eudesmanolide-type sesquiterpene lactone. The compound demonstrated an *in vitro* IC₅₀ of 1.865 μM against a chloroquine-sensitive strain (D10) of *P. falciparum*. Synthetic analogues of the compound confirmed an absolute requirement that the α-methylene lactone be present in the eudesmanolide before significant anti-malarial activity was observed. This feature is absent in the artemisinins and suggests a different mode of action. Microarray data analysis identified 572 unique genes that were differentially expressed as a result of the treatment and gene ontology analysis identified various biological processes and molecular functions that were significantly affected. Comparison of the dehydrobrachylaenolide treatment transcriptional dataset with a published artesunate (also a sesquiterpene lactone) dataset revealed little overlap. These results strengthen the notion that the isolated compound and the artemisinins have differentiated modes of action.

Conclusions: The novel mode of action of dehydrobrachylaenolide, detected during these studies, will play an ongoing role in advancing anti-plasmodial drug discovery efforts.

* Correspondence: dmancama@csir.co.za

¹Biosciences, CSIR, PO Box 395, Pretoria, 0001, South Africa

Full list of author information is available at the end of the article

Background

The most critical problem facing malaria treatment today is resistance to anti-plasmodial drugs. The emerging resistance of *Plasmodium falciparum* to the only affordable anti-malarials, chloroquine and sulphadoxine/pyrimethamine, and now even the last effective class of antimalarials, the artemisinins [1,2], undermines efforts to eliminate or even manage effectively this deadly disease. Hence, there is continued interest in the discovery of bioactive natural compounds with unique structures that may lead to anti-malarial drugs with novel modes of action [3-5].

South Africa boasts a rich biodiversity with more than 22,600 indigenous plants, representing about 9% of all higher plants on Earth [6]. There is also a long history of the use of plants in African traditional healthcare systems. This natural resource and indigenous knowledge, together with the historical success of the plant-derived anti-malarials (*i.e.* quinine, artemisinin) and the universal need for new drugs, prompted a national consortium initiative to discover novel anti-plasmodial agents from South African plants [7].

One of the plants selected for this study was *Dicoma anomala*, an erect, suberect or prostrate herb bearing aromatic semi-woody tubers at the base of a woody subterranean stem. This grassland species is widely distributed in sub-Saharan Africa, and is morphologically diverse, resulting in the recognition of several infraspecific taxa. Two subspecies occur in South Africa: *D. anomala* subsp. *anomala* and *D. anomala* subsp. *gerrardii* [4].

The numerous ethnomedicinal uses of *D. anomala*, which range from the treatment of coughs and colds, fevers, ulcers, dermatosis, venereal diseases, labour pains, dysentery, intestinal parasites, stomach pains, toothache and internal worms, can be linked to several pharmacological properties: anti-bacterial, anti-helminthic, anti-viral, anti-plasmodial, anti-spasmodic, wound healing, analgesic and anti-inflammatory [8-11]. A previous study reported the anti-bacterial and anti-inflammatory properties of the root extracts of *D. anomala* [9]. Another study demonstrated *in vitro* anti-cancer activity of extracts of a related species, *Dicoma capensis* [12,13].

Phytochemical investigations of *D. anomala* have identified several classes of secondary metabolites; including acetylenic compounds, phenolic acids, flavonoids, sesquiterpene lactones, triterpenes and phytosterols [14-16]. The investigation of a dichloromethane extract of the roots of *D. anomala* resulted in the isolation of asymmetrical sesquiterpene dimers with potent anti-plasmodial properties [17,18]. Based on this finding and the reported use of *D. anomala* in the treatment of fevers, a primary symptom of malaria [8,9], an ethyl acetate (EtOAc) extract of the roots of *D. anomala* subsp. *gerrardii* was assayed against a chloroquine-sensitive strain of *P. falciparum*. Its activity warranted further investigation

and a sesquiterpene lactone, dehydrobrachylaenolide (Figure 1), was isolated by column chromatography and found to show *in vitro* activity [11]. Structure-activity relationship experiments (through the generation and assessment of simple synthetic analogues) confirmed the requirement for activity as the α -methylene lactone moiety, a feature absent in artemisinin anti-malarials (artesunate, Figure 2). The compound was further investigated through transcriptome analysis and comparisons were drawn between the isolated compound and a related sesquiterpene lactone, artesunate (Figure 2). Comparative analysis revealed little overlap and confirmed likely different modes of action.

Methods


Plant collection and extraction


Collection of rootstocks of *D. anomala* subsp. *gerrardii* was undertaken in the Brits region of the North West Province of South Africa during February 2008. A voucher (BP 01455) was deposited at the National Herbarium of South Africa (Pretoria), and the identity of this taxon confirmed by Dr E. Retief.

A total of 5.6 kg of fresh rootstock was oven dried (30°C) and ground with a hammer mill to yield 3.7 kg of finely processed plant material. Of this, 3.4 kg of the processed material was consecutively extracted with 3 volumes of EtOAc (15 L) at room temperature over 3 days. The filtered extract was concentrated under reduced pressure on a rotary evaporator at 60°C and further dried in a vacuum desiccator for 96 h to remove all traces of solvent. The extraction yielded 48 g of brown gum (1.3% w/w of dry plant material).

Isolation and identification of dehydrobrachylaenolide

Solvent partitioning of the crude extract was used to divide the extract into three fractions with different





polarities. The extract (1 g) was dissolved in 100 mL of aqueous methanol (MeOH/H₂O 9:1, v/v) and extracted with hexane (3 × 100 mL). MeOH was removed from the aqueous methanolic layer under vacuum on a rotary evaporator; the remaining solution was diluted to 100 mL with H₂O and extracted with dichloromethane (DCM) (3 × 100 mL). The DCM layers were combined and dried over anhydrous Na₂SO₄, filtered and concentrated under vacuum on a rotary evaporator to give a DCM-soluble fraction. This process was scaled up for the remaining crude extract.

Large-scale purification of the DCM-soluble fraction was performed by liquid chromatography in batches of 5 - 10 g of extract on 400 - 500 g of silica gel 60 (0.063 - 0.2 mm) under reduced pressure, using EtOAc/hexane/DCM/MeOH and acetone/DCM/MeOH gradients. Pooled fractions were combined on the basis of similarity of chemical profile as determined by thin-layer chromatography (TLC). Crude fractions 1A-1L were concentrated under vacuum on the rotary evaporator. Fractions 1D-1H were combined (3.5 g) on the basis of similarity of their TLC profile and subjected to further column chromatography using a 90 cm column packed with silica gel and eluted with an EtOAc/hexane/DCM/MeOH isocratic solvent mixture (9:45:45:1, v/v) to give fractions 2A-2N. The fractions were combined on the basis of similarity of the chemical composition determined by TLC analysis. Further fractionation of 2F (0.4 g) was achieved by means of flash chromatography, using a 40 cm flash column, packed with flash silica gel (silica gel 60) and eluted with a hexane/DCM/EtOAc/MeOH isocratic solvent mixture (45:45:9:1, v/v). This yielded compound 1, which was recrystallized from 2-propanol to yield 400 mg (0.013% w/w of dry plant material) of white orthorhombic crystals.

Compound 1 was identified using standard one- and two-dimensional nuclear magnetic resonance spectroscopic (NMR) experiments; electrospray-ionization mass

spectrometry (ESI-MS); X-ray crystallography and by direct comparison with published spectral data [19-21].

NMR analysis was carried out on a Varian 400 MHz Unity spectrometer. The mass spectral data were obtained from a hyphenated HPLC-UV/MS instrument (HPLC Waters Alliance 2690 system, equipped with a Waters 996 photodiode array detector and a triple quadrupole Quattro LC Micro mass spectrometer). The mass spectrometer was set to operate in both the ESI⁻ and ESI⁺ modes (49 - 478 amu) with a gain of 10; the cone voltage was varied between 20 and 70 eV; the desolvation temperature was 450°C; and the source block temperature was set at 120°C. Crystallography experiments were conducted on an Oxford Diffraction Excalibur-2 CCD area detector diffractometer, using Mo-K α X-radiation and a graphite-crystal monochromator. Optical rotations were measured in chloroform at room temperature on a Perkin-Elmer 241 polarimeter at 589 nm (Na D-line) using a 1 dm cell.

Parasite cultures

Asexual *P. falciparum* chloroquine-sensitive 3D7 and D10 cultures, as well as chloroquine-resistant K1 strain cultures, were maintained and synchronized according to established methods [22,23] in an atmosphere consisting of 5% oxygen, 5% carbon dioxide and 90% nitrogen. The parasites were maintained at a 5% haematocrit in RPMI 1640 medium supplemented with 25 mM HEPES, 22 mM glucose, 0.0088% hypoxanthine, 40 μ g/mL gentamycin (all Sigma) and 0.5% Albumax (Invitrogen).

In vitro anti-malarial assay

The anti-plasmodial activities of the extracts and pure compounds were determined against the chloroquine-sensitive D10 and the chloroquine-resistant K1 strains via the parasite lactate dehydrogenase (pLDH) assay [24]. All test substances were stored at -20°C prior to testing. Stock solutions of test substances were prepared in 10% MeOH or 10% DMSO (in water), depending on the solubility, and diluted in Millipore water to prepare 2 mg/mL solutions, which were stored at -20°C. Chloroquine diphosphate (Sigma) was used as a reference drug in all experiments. The test substances were evaluated as ten serial two-fold dilutions (0.2 - 100 μ g/mL final concentration) in medium (two replicates per concentration point) in duplicate wells. The highest concentration of organic solvent that the parasites were exposed to was 0.5%, which was shown to have no measurable effect on parasite viability [7]. Test solutions were mixed with suspensions of infected human red blood cells to achieve a final haematocrit of 1% and parasitaemia of 2% and incubated for 48 h in microtitre plates (250 μ L final volume). Incubation conditions were as described above for the routine maintenance of the *P. falciparum* cultures. The

IC₅₀ values, serving as a measure for anti-plasmodial activities, were calculated by non-linear regression dose-response analysis using GraphPad Prism v.4.0 software.

***In vitro* cytotoxicity assay**

Compounds were tested for *in vitro* cytotoxicity against a Chinese hamster ovary (CHO) cell line using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay [25]. The CHO cells were cultured in DMEM: Hams F-12 medium (1:1) supplemented with 10% heat-inactivated foetal calf serum (FCS) and gentamycin (0.04 µg/mL) (Highveld Biological, RSA). Samples were dissolved in 10% MeOH. Stock solutions (2 mg/mL) were prepared and were stored at -20°C until use. The samples were added to CHO cells as five ten-fold serial dilutions ranging from 100 - 0.01 µg/mL. A serial dilution of emetine (100 - 0.001 µg/mL) was used as a positive control. Cells were seeded in 96-well plates at a concentration of 10⁵/mL (100 µL per well) and incubated at 37°C for 24 h in a humidified 5% CO₂-air atmosphere. The medium was subsequently aspirated from the wells and replaced with 200 µL of the test compound dilutions. The microplates were incubated at 37°C for 48 h, after which 25 µL of sterile MTT (5 mg/mL in PBS) was added to each well and incubation was continued for 4 h at 37°C. Formazan crystals formed by viable cells were dissolved in DMSO and quantitated by measuring absorbance at 540 nm in a microtitre plate reader (Cambridge Technologies). Cell viabilities were calculated relative to reference wells containing no test compounds (positive cell controls) and no cells (background controls), plotted against log[test sample] and IC₅₀ values derived by non-linear regression analysis using GraphPad Prism v.4.0 software.

Generation of synthetic analogues of compound 1

Information on the synthesis of compound 1 analogues for structure-activity relationship studies is provided [see Additional file 1].

Transcriptome analysis

Parasite drug treatment and RNA extraction

P. falciparum 3D7 cultures were treated with 12.5 µM of compound 1, corresponding to an inhibitory concentration of IC₉₉ as determined from dose-response curves. A morphological comparison between compound 1 treated versus untreated parasites was performed to assess the effect of treatment and to establish sampling times, by examining the stage-specific progression of parasites across the intra-erythrocytic development cycle. The solvent (DMSO) or compound 1 was added in the window shortly after red blood cell (RBC) invasion and parasite development was monitored 6 hourly over a 48 h period using conventional Giemsa-stained smears. Fresh

cultures were scaled up to 50 ml (5% hematocrit, 10% parasitemia), synchronized twice and treated with compound 1 in the window around invasion. Fifteen milliliters of culture was harvested at each of the stages used for transcriptional analyses (2, 6 and 12 hpt). Similar volumes were harvested from untreated *P. falciparum* 3D7 control cultures at the same time points. Parallel drug treatments were conducted, serving as biological replicates. RNA was extracted from the frozen erythrocyte pellets as described [26].

Universal Reference RNA (URR) pool, cDNA synthesis and hybridization

The URR pool was constructed from mixed-stage cultures as described [26]. cDNA synthesis and hybridizations was as described in [26], with the exception that 40 pmoles of each dye was hybridized to each array, utilising Cy3 (sample) and Cy5 (reference) dyes from GE Healthcare (#RPN5661), specifically optimized for nucleic acid labelling.

Microarray data analysis and real-time quantitative PCR (RT-qPCR)

Generation of GenePix results (gpr) files, LIMMA and MARRAY analysis in the R computing environment, calculation of Pearson correlation coefficients and determination of differentially expressed genes were performed as detailed in [26]. RT-qPCR was performed on an Applied Biosystems 7500 Fast cycler (Carlsbad, California, USA) as described [26]. qPCR primers were designed using Primer3 Plus [27] and sequences are available on request. PCR efficiencies for each sample were calculated using LinRegPCR, software described in [28]. Fluorescence data per cycle of each sample is exported from the Applied Biosystems 7500 Fast cycler, from which the efficiencies of individual samples were calculated. These efficiencies were used to calculate relative expression in a mathematical model described by Pfaffl [29]. Gene ontology analyses were performed using the Micro Array Data Interface for Biological Annotation (MADIBA) software [30].

Results

Isolation and identification of compound 1

In the search for novel anti-malarials from South African plants, an EtOAc extract of *D. anomala* subsp. *gerrardii* was screened against the chloroquine-sensitive D10 strain of *P. falciparum* using the pLDH assay. The extract exhibited an IC₅₀ of 1.4 µg/mL [11].

A phytochemical investigation of this extract resulted in the isolation of a major compound, compound 1. NMR analysis revealed the presence of an α -methylene- γ -lactone moiety and two fused cyclohexane rings forming the skeleton of the eudesmanolide-type sesquiterpene lactone. The A ring was found to possess a 1,2-endocyclic double bond, a carbonyl at C-3 and an additional exocyclic methylene at C-4. Compound 1 was subsequently identified as

3-oxoeudesma-1,4(15),11(13)-triene-12,6 α -lide, which was identical to the structure of dehydrobrachylaenolide (Figure 1, see Additional file 2), previously isolated from *Brachylaena transvaalensis* [20], *Hieracium intybaceum* [31] and various *Dicoma* species [16], all of the Asteraceae family. A successful chemical synthesis, which confirmed the structure and absolute configuration of dehydrobrachylaenolide, has been reported [21].

The relative configuration of the asymmetric centres at C-5, C-6 and C-7 was deduced to be *trans* based on the size of the observed ¹H NMR coupling constants and NOE correlations. This was in good agreement with previously reported configuration data for dehydrobrachylaenolide [16,32], and was subsequently confirmed by X ray crystallography and optical rotation studies [33].

***In vitro* anti-plasmodial activity of dehydrobrachylaenolide and its synthetic analogues**

The eudesmane-type natural compounds are expected to have various biological activities due to their chemical structure [21] but the anti-malarial activity of dehydrobrachylaenolide has not yet been reported. Sesquiterpene lactones are known to have anti-plasmodial activities [34-37] and, therefore, the isolated dehydrobrachylaenolide was tested for potential activity against *P. falciparum*. Toxicity against mammalian CHO cells was used to derive a therapeutic index for the test compound [11]. The results are summarized in Table 1.

The compound had an IC₅₀ of 1.865 μ M (0.455 μ g/mL) against the chloroquine-sensitive D10 strain and 4.095 μ M (1.0 μ g/mL) against the chloroquine-resistant K1 strain when tested *in vitro* [see Additional file 3]. Dehydrobrachylaenolide can therefore be considered a hit, because it complies with the basic criteria for anti-parasitic drug discovery [38] with an *in vitro* IC₅₀ against whole protozoa of ≤ 1 μ g/ml and a selectivity of close to ten-fold more against the chloroquine-sensitive parasites than against the CHO cells (see therapeutic index, Table 1).

The working assumption in assessing active functionality was that the levels of unsaturation in the eudesmanolide, in particular the α -methylene lactone within dehydrobrachylaenolide (Figure 1), would be responsible for the

observed activity. Several analogues (2 - 6) were synthesized to investigate the structure-activity relationships within dehydrobrachylaenolide and are depicted in Table 2. Due to the time frames involved in obtaining permits for plant collection, plant collection, and metabolite isolation, a semi-synthetic analogue (2) of dehydrobrachylaenolide (1) was generated by reducing the α -methylene appended to the ketone in the A-ring and increasing the unsaturation of this ring. The synthetic analogue (2) generated lacked the anti-malarial potency of the natural product (1), being six-fold less active against the D10 strain. However, this activity was considered sufficient to examine functional group relationships to activity. Reduction of the α -methylene appended to the lactone yielded santonin (3), which was devoid of any significant anti-malarial activity or mammalian toxicity (as measured by activity against CHO) at the upper concentrations of the biological assays. As expected, complete removal of unsaturation in the A-ring resulted in the generation of a compound (4) lacking both activity and toxicity. Re-introduction of the exocyclic methylene to the lactone resulted in a singly unsaturated derivative (5) which displayed moderate anti-malarial activity (about half the potency of the parent (2)). The CHO-based toxicity of this species was, however, substantially reduced (about twenty-fold from the synthetic parent (2) and almost ten-fold from the natural product). The re-introduction of limited unsaturation in the A-ring (6), (tested as a mixture) resulted in no significant improvement in anti-malarial activity with respect to (5), but increased mammalian cell toxicity.

Transcriptome analysis of dehydrobrachylaenolide inhibition

Culturing, drug treatment and RNA extraction

A morphological analysis was performed with dehydrobrachylaenolide to ascertain the point during intra-erythrocytic development at which *P. falciparum* 3D7 growth was affected. Drug treatments were performed in the window following RBC invasion (i.e. during the early ring stage growth phase). No significant morphological differences were observed between treated and control cultures immediately following drug administration

Table 1 *In vitro* activity of dehydrobrachylaenolide against *P. falciparum*

Compound	D10 IC ₅₀ (μ M) n = 8	K1 IC ₅₀ (μ M) n = 4	CHO IC ₅₀ (μ M) n = 2	D10 TI	K1 TI
Dehydrobrachylaenolide	1.865 \pm 0.254	4.095 \pm 0.579	17.199	9.2	4.2
Chloroquine	0.038	0.200	35.800	942	179

D10 = *P. falciparum* - chloroquine-sensitive strain







K1 = *P. falciparum* - chloroquine-resistant strain

CHO = Chinese hamster ovary cells

n = number of technical replicates averaged - each independent experiment performed in duplicate

TI = Therapeutic index i.e. CHO IC₅₀/anti-plasmodial IC₅₀

Table 2 Analogues generated for determination of active sub-structures

Structure	D10 strain IC ₅₀ (μM) n = 2	K1 strain IC ₅₀ (μM) n = 2	CHO IC ₅₀ (μM) n = 2
	1.865*	4.095 [#]	17.2
	11.5	9.05	7.01
	> 40	NT	> 400
	> 40	NT	> 400
	22.1	NT	124
	16.9	NT	41.9


n = number of technical replicates averaged - each independent experiment performed in duplicate with several independent experiments performed for the parent compound dehydrobrachylaenolide.

* n = 8

[#] n = 4

(T = 0), while at 6 h post-treatment (hpt, T = 6) the majority of the treated parasite cultures were already observed to be developing slower than the untreated cultures (Figure 3). Clear differences in morphological development were visible at 12 hpt (T = 12), where virtually all treated parasites were smaller in size and abnormal in shape compared to the control cultures. Treated parasites remained arrested in the ring phase throughout

the rest of the 48-hour intraerythrocytic cycle, by the end of which they were observed to be disintegrated, shrivelled or compact. Based on these morphological observations and the apparent rapid effect of dehydrobrachylaenolide on *P. falciparum* development, sampling times for transcriptional analysis were subsequently determined as 2, 6 and 12 hpt. RBC Giemsa-stained smears taken at these time points confirmed the onset of



the inhibitory effect of dehydrobrachylaenolide within this timeframe.

Gene expression profiling of *P. falciparum* treated with dehydrobrachylaenolide

A microarray reference design experimental strategy, similar to that described in [26] was employed to ascertain global gene expression in parasites perturbed with dehydrobrachylaenolide. Labelled cDNA was hybridized to Operon oligonucleotide microarrays, interrogating 4585 unique genes. All data has been deposited in the NCBI's Gene Expression Omnibus (GEO) database, GEO number GSE29874. Pearson correlation coefficient values for both technical and biological variation were calculated in Microsoft Excel. Technical variation across all arrays was calculated to be 0.89 ± 0.13 ; whereas biological variation across all slides was calculated as 0.78 ± 0.16 . Datasets were collated into untreated (UT₂, UT₆ and UT₁₂) and treated (T₂, T₆ and T₁₂) samples at each time point before calculation of Pearson correlation coefficients between drug-treated and control samples. Correlation coefficients suggested that parasites remained in similar states across the different time points after dehydrobrachylaenolide treatment, as can be gauged from coefficients between T₂ and T₆ (0.88) and T₆ and T₁₂ (0.91). The correlation between T₂ and T₁₂ was calculated as 0.82, indicating a growth delay close to or around 6 hpt. This notion is strengthened by the fact that Pearson correlation between UT₆ and T₁₂ was 0.70, while the parallel comparison (UT₁₂ and T₁₂) was calculated at 0.57. For differential gene expression analyses, T₂ parasites were contrasted to UT₂, and T₁₂ and T₆ parasites contrasted to UT₆. A full table of correlation values between all collated samples is provided [see Additional file 4]. A total of 572 unique genes were differentially regulated (cumulatively across all time points) at least two-fold and with a false discovery rate (FDR) cut off of 5% following parasite perturbation with dehydrobrachylaenolide (all genes listed in Additional file 5). The number of differentially regulated genes represents 12.5% of the genes present on the array. Of these, 297 were up-regulated (52% of the total), and 275 downregulated (48% of the total). The number of differentially expressed transcripts increased with time following drug addition, as expected from Pearson correlations, which indicates a drug effect on parasite transcription at approximately 6 hpt. Affected transcripts for T₂, T₆ and T₁₂ were 134, 291 and 378, respectively. Several transcripts were differentially expressed at more than one time point (e.g. T₂ and T₆ or T₆ and T₁₂). Due to the cytotoxic nature of sesquiterpene lactones [39,40], the high treatment dose (IC₉₉) and the rapid time of action of dehydrobrachylaenolide, the transcriptional changes observed at the last time point (T = 12) were regarded as less informative concerning mode of action and were not analysed further. In a

related transcriptome investigation of *P. falciparum* parasites treated with lethal doses of artesunate (a derivative of the sesquiterpene lactone artemisinin), time points were harvested after 90 minutes and 3 hours resulting in 398 differentially affected genes [41].

Differentially expressed transcripts were validated by analysing their expression by real-time quantitative PCR (RT-qPCR). The expression of three transcripts (MAL7P1.93 (mitochondrial ribosomal protein S8, putative), MAL7P1.175 (hypothetical protein) and PFL0055 c (protein with DNAJ domain (resa-like), putative)) was evaluated by qPCR, utilising PFL0625 c (eukaryotic translational initiation factor 3) as an endogenous control, as described previously [26].

There was a good concordance between expression levels from array analysis and those determined by qPCR (Table 3). At 2 hpt, the expression values (log₂) for MAL7P1.93 were 1.09 and 1.29 for array and qPCR analyses respectively, and those for MAL7P1.175 were 1.89 and 2.02. Furthermore, the array expression values for the endogenous control were unchanged (log₂ values at 2 and 6 hpt were 0.0037 and -0.0946, respectively).

MADIBA analyses for metabolic pathways enriched following drug perturbation indicated that several metabolic pathways were involved in the parasite's response to perturbation with dehydrobrachylaenolide. At T₂, transcripts involved in 20 metabolic pathways were affected; at T₆, this increased to 26. The only metabolic pathway with an appreciable p-value (in Fisher's contingency test in MADIBA) was "Biosynthesis of type II polyketide backbone", affected at T₆ (p = 0.190). However, there is scant information regarding this pathway in the parasite. Higher p-values are expected from these analyses, since all affected transcripts at a given time point are submitted for analyses, without clustering, as described [26].

Gene Ontology (GO) analysis for genes affected by dehydrobrachylaenolide treatment, for both Biological Process and Molecular Function, were performed using MADIBA software [30]. Biological Process GO terms

Table 3 Comparison of expression values (log₂)* as determined by transcriptome analysis and RT-qPCR

PlasmoDB ID	array	RT-qPCR	array	RT-qPCR
	2 hpt	2 hpt	6 hpt	6 hpt
MAL7P1.93	1.09	1.29	1.35	2.12
MAL7P1.175 (oligo 1)	1.89	2.02	1.27	2.11
MAL7P1.175 (oligo 2)	1.98		1.7	
PFL0055c	1.5	3.38	2.17	2.61
eTFIII (PFL0625c)	0.0037	housekeeping	-0.0946	housekeeping

*Data numerical values were transformed to the log base 2 in order to treat gene induction and repression on an equal level mathematically.

occurring at multiple time points (T_2 and T_6 ; at corrected $p < 0.05$) included chromatin silencing and dephosphorylation. Additional Biological Process GO terms included electron transport and DNA replication (T_2) and tRNA modification (T_6). The Molecular Function GO term chromatin binding appeared at both T_2 and T_6 ; as did histone binding. In addition, pepsin A activity (T_2), actin binding and sugar metabolism (T_6) were affected. The GO terms are listed in Table 4.

Discussion

The EtOAc extract of *D. anomala* subsp. *gerrardii* showed sufficient activity against *P. falciparum* to warrant further investigation. Compound 1, dehydrobrachylaenolide, isolated as a major component of this extract, was subsequently screened for its anti-plasmodial activity and found to exhibit some activity against a chloroquine-sensitive D10 strain and a chloroquine-resistant K1 strain of *P. falciparum*. This is the first report of anti-malarial activity associated with this compound.

Dehydrobrachylaenolide was originally isolated from the roots of *Brachylaena transvaalensis*, from which its name was derived [20]. Several biological activities were reported for this natural product. These included inhibitory activity toward induction of intracellular adhesion molecule-1 (ICAM-1) [21] and anti-bacterial properties [42]. It was also shown to have significant anti-cancer activity in the NCI's 60-cell line panel, with a selectivity trend towards the leukaemia sub-panel [11].

The activity of dehydrobrachylaenolide against the chloroquine-sensitive strain ($IC_{50} = 1865$ nM) is within an order of magnitude of that of quinine ($IC_{50} = 194$ nM) [43]. Furthermore, against the chloroquine-sensitive

strain, the compound has a therapeutic index of 9.2, which is close to the acceptable value of 10 for potential development [38].

To establish the chemical moieties responsible for the inhibition of *P. falciparum* inhibition by dehydrobrachylaenolide, synthetic analogues of dehydrobrachylaenolide were tested against *P. falciparum* utilising the pLDH assay. From these studies, it was concluded that the anti-malarial activity was mainly attributable to the conjugate acceptor properties of the methylene lactone and the methylene ketone (in the A-ring, Figure 1). The natural product possessed two readily accessible acceptor groups of this type and the absence or inaccessibility of the methylene ketone was responsible for a ten-fold enhancement in activity without concomitant increase in toxicity (or, possibly, a two-fold reduction in toxicity), suggesting that toxic liabilities were largely associated with the methylene lactone. Further examinations relating to the role of A-ring geometry and functionalization could be warranted.

Previously, the authors successfully applied a functional genomics approach to study the effects on the *P. falciparum* transcriptome of treatment with cytostatic drugs (i.e. DFMO/MDL73811 co-inhibition [44] and cyclohexylamine [26]). In the study presented here, gene expression profiling was performed on a parasitic cytotoxic compound, dehydrobrachylaenolide, subsequent to its isolation, identification, demonstrated anti-malarial activity and structure-activity relationship (SAR) studies. Gene expression profiling of another sesquiterpene lactone, artesunate [41], reported 398 genes that were differentially expressed compared to untreated *P. falciparum* parasites. Further to the SAR analyses, comparison

Table 4 Gene Ontology terms enriched following addition of dehydrobrachylaenolide at 2 and 6 hours post-treatment (at $p < 0.05$)

Time post treatment	Biological process	Molecular function	p-value	Corrected p-value (false discovery rate, $p < 0.05$)
2 hpt	chromatin silencing		0.00056108	0.0026184
	dephosphorylation		0.0016571	0.0069599
	electron transport		0.018276	0.036552
	DNA replication		0.027838	0.048717
	chromatin binding		0.00076337	0.0049195
	histone binding		0.0018045	0.0095146
	pepsin A activity		0.019635	0.049515
6 hpt	chromatin silencing		0.0022313	0.0096688
	dephosphorylation		0.0064848	0.018577
	tRNA modification		0.012566	0.029149
	chromatin binding		0.00047321	0.0031305
	actin binding		0.003905	0.011994
	sugar metabolism		0.0082591	0.022196
	histone binding		0.0082591	0.022196

of the artesunate dataset with the dehydrobrachylaenolide dataset of 340 genes (unique genes differentially expressed at T₂ and T₆), resulted in only 7.65% (26 genes of the 340) overlap. This marked difference underscores their probable different modes of action, particularly since, despite being a sesquiterpene lactone, dehydrobrachylaenolide does not contain the endoperoxide bridge that is characteristic of the artemisinins and key to their biological activity [45]. In contrast, the α -methylene- γ -lactone moiety, as well as the conformation of the A-ring (Figure 1) of dehydrobrachylaenolide, which is absent in the artemisinins, is significant for various biological activities of the eudesmane sesquiterpene lactones [11,46]. The structure-activity relationship studies performed for dehydrobrachylaenolide confirmed this.

Conclusions

In this investigation the active constituent of *Dicoma anomala* subsp. *gerrardii* was isolated and identified as dehydrobrachylaenolide, an eudesmanolide-type sesquiterpene lactone. The compound demonstrated *in vitro* anti-malarial activity against a chloroquine-sensitive strain of *P. falciparum*. Structure-activity relationship studies indicated that exocyclic methylene residues on both the lactone and A-ring appear to be responsible for the observed anti-malarial activity [11]. This methylene lactone moiety is absent in the artemisinin anti-malarials, indicating a differentiated mode of action to the artemisinins. Gene expression profiling via microarray strengthened the notion that dehydrobrachylaenolide displays a different mode of action compared to artesunate [41].

In light of the development of resistance against standard anti-malarials (now also including the artemisinins [1,2]) and the quest for new drugs with novel modes of action, this finding is significant and underscores the potential of dehydrobrachylaenolide as a potential drug lead. Some recent examples of so-called pro-drugs of sesquiterpene lactones, namely ambrosin, arglabin, parthenin and parthenolide, demonstrate the value of sesquiterpene lactones as lead compounds for the development of pharmaceuticals [47-52].

It can be concluded that dehydrobrachylaenolide could play a valuable role as a drug lead. Further mechanistic studies and an *in vivo* dose response toxicity study would be necessary to gain in-depth knowledge of the structural requirements for selectivity, with respect to the desired biological activity, and systemic toxicity.

Additional material

Additional file 1: Generation of synthetic analogues. The file contains a description of the synthesis of dehydrobrachylaenolide analogues for structure-activity relationship studies.

Additional file 2: Chemical and physical data (including the NMR assignments) of compound 1. The file contains the chemical and physical data (including the NMR assignments) of compound 1 used to identify it as dehydrobrachylaenolide.

Additional file 3: Dose response and survival curves for dehydrobrachylaenolide assayed against *P. falciparum* and the CHO cell-line. The file contains examples of dose-response curves of dehydrobrachylaenolide obtained for the chloroquine-sensitive strain D10 and chloroquine-resistant strain K1.

Additional file 4: Microarray correlation values between samples at 2, 6 and 12 hours post-treatment. Correlation values between collated microarray samples at 2, 6 and 12 hours post-treatment.

Additional file 5: Differentially expressed genes identified in *P. falciparum* following dehydrobrachylaenolide treatment. File contains lists of differentially up- and downregulated gene identifications (IDs), annotations and relative expression values at each time point following dehydrobrachylaenolide treatment.

Acknowledgements and Funding

The project was funded by the South African Department of Science and Technology, the NRF Innovation fund (NDDP) (Grant Number TM1002FP) and CSIR Parliamentary Grant. Synthetic and bioactivity evaluation work was abstracted from a thesis presented in the fulfilment of the requirements for an MSc by MM van der Merwe. The authors wish to thank Heinrich Hoppe for critical revision of the manuscript.

Author details

¹Biosciences, CSIR, PO Box 395, Pretoria, 0001, South Africa. ²School of Chemistry (Pietermaritzburg), University of KwaZulu-Natal, Private Bag X01, Scottsville, 3209, South Africa. ³Forestry and Agriculture Biotechnology Institute, University of Pretoria, Pretoria, 0001, South Africa. ⁴Ethnobotany Unit, South African National Biodiversity Institute, PO Box 52099, Berea Road, 4007, South Africa/School of Chemistry, University of KwaZulu-Natal, Private Bag X01, Scottsville, 3209, South Africa. ⁵Pharmacology Division, Department of Medicine, University of Cape Town, K-45 OMB GSH, Observatory, 7925, South Africa. ⁶African Centre for Gene Technologies, PO Box 75011, Lynnwood Ridge, Pretoria, 0040, South Africa.

Authors' contributions

JVWB performed all transcriptional analyses, its validation and analysis and contributed to drafting the manuscript, MMvdM was responsible for the background studies, isolation, structural elucidation and initial *in vitro* data interpretation of anti-malarial activity, ACvB assisted with data interpretation, drafting and finalizing the manuscript, PP drafted the natural product and *in vitro* bioassay sections of the manuscript, BGC was responsible for parasite drug treatments for morphological and gene expression experiments, EMM performed the chemical synthesis of the dehydrobrachylaenolide analogues, CP provided technical input into the manuscript and designed the synthetic study, FvH supervised the isolation and structural elucidation aspects, NRC was responsible for plant selection, and botanical/ethnomedicinal information included in this manuscript, PJS was responsible for the *in vitro* biological assay data, DTM contributed to study conceptualization, morphology profiling, and drafting the manuscript, VJM was involved in the plant selection and collection, structural elucidation and *in vitro* data interpretation. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 29 July 2011 Accepted: 11 October 2011

Published: 11 October 2011

References

1. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Pujjalon O: **Resistance of *Plasmodium falciparum* field isolates to *in-vitro* artemether and point mutations of the SERCA-type PfATPase6.** *Lancet* 2005, **366**:1960-1963.

2. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Arieu F, Hanpithakpong W, Lee SK, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ: **Artemisinin resistance in *Plasmodium falciparum* malaria.** *N Engl J Med* 2009, **361**:455-467.
3. Fidock DA: **Priming the antimalarial pipeline.** *Nature* 2010, **465**:297-298.
4. Kaur K, Jain M, Kaur T, Jain R: **Antimalarials from nature.** *Bioorg Med Chem* 2009, **17**:3229-3256.
5. Pillay P, Maharaj VJ, Smith PJ: **Investigating South African plants as a source of new antimalarial drugs.** *J Ethnopharmacol* 2008, **119**:438-454.
6. Van Wyk BE, Gericke N: *People's plants: A guide to useful plants of Southern Africa* Pretoria: Briza Publications; 2000.
7. Clarkson C, Maharaj VJ, Crouch NR, Grace OM, Pillay P, Matsabisa MG, Bhagwandin N, Smith PJ, Folb PI: **In vitro anti-plasmodial activity of medicinal plants native to or naturalised in South Africa.** *J Ethnopharmacol* 2004, **92**:177-191.
8. Roberts M: *Indigenous healing plants* Halfway House: Southern Book Publishers; 1990.
9. Gelfand M, Mavi S, Drummond RB, Ndemera B: *The traditional medicine practitioner in Zimbabwe* Gweru (Zimbabwe): Mambo Press; 1985.
10. Von Koenen E: *Medicinal, poisonous and edible plants in Namibia* Windhoek: Klaus Hess; 2001.
11. Van der Merwe MM: *Bioactive sesquiterpenoids from *Dicoma anomala* subsp. *gerrardii** MSc thesis, University of KwaZulu-Natal; 2008.
12. Steenkamp V, Mathivha E, Gouws MC, Van Rensburg CE: **Studies on antibacterial, antioxidant and fibroblast growth stimulation of wound healing remedies from South Africa.** *J Ethnopharmacol* 2004, **95**:353-357.
13. Steenkamp V, Gouws MC: **Cytotoxicity of six South African medicinal plant extracts used in the treatment of cancer.** *S Afr J Bot* 2006, **72**:630-633.
14. Bremer K: *Asteraceae. cladistics and classification* Portland, Oregon: Timber Press; 1994.
15. Ortiz A: **A phylogenetic analysis of *Dicoma* Cass. and related genera (Asteraceae: Cichorioideae: Mutisieae) based on morphological and anatomic characters.** *Ann Missouri Bot Gard* 2001, **87**:459-481.
16. Bohlmann F, Singh P, Jakupovic J: **New germacranolides and other sesquiterpene lactones from *Dicoma* species.** *Phytochemistry* 1982, **21**:2029-2033.
17. Matsabisa GM, Campbell WE, Folb PI, Smith PJ: **Treatment of parasitic infections in humans and animals.** 2006, (WO/2006/048734).
18. Matsabisa GM, Campbell WE, Folb PI, Smith PJ: **Treatment of parasitic infections in humans and animals.** 2009, (JA/2009/0304832).
19. Barrera JB, Breton JL, Fajardo M, Gonzalez AG: **Terpenoids from the *Sonchus* U1 *Tuberiferine* from *Sonchus tuberifer* Svnt.** *Tetrahedron Lett* 1967, **3475**-3476.
20. Bohlmann F, Zdero C: **Sesquiterpene lactones from *Brachylaena* species.** *Phytochemistry* 1982, **21**:647-651.
21. Higuchi Y, Shimoma F, Koyanagi R, Suda K, Mitsui T, Kataoka T, Nagai K, Ando M: **Synthetic approach to exo-endo cross-conjugated cyclohexadienones and its application to the syntheses of dehydrobrachylaenolide, isodehydrochamaecynone, and trans-isodehydrochamaecynone.** *J Nat Prod* 2003, **66**:588-594.
22. Trager W, Jensen JB: **Human malaria parasites in continuous culture.** *Science* 1976, **193**:673-675.
23. Lambros C, Vanderberg JP: **Synchronisation of *Plasmodium falciparum* erythrocytic stages in culture.** *J Parasitol* 1979, **65**:418-420.
24. Makler MT, Ries JM, Williams JA, Bancroft JE, Piper RC, Gibbins BL, Hinrichs DJ: **Parasite lactate dehydrogenase as an assay for *Plasmodium falciparum* drug sensitivity.** *Am J Trop Med Hyg* 1993, **48**:739-741.
25. Mosmann T: **Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.** *J Immunol Methods* 1983, **65**:55-63.
26. Becker JW, Mtwisha L, Crampton BG, Stoychev S, Van Brummelen AC, Reeksting SB, Louw AI, Birkholtz L-M, Mancama DT: ***Plasmodium falciparum* spermidine synthase inhibition results in unique perturbation-specific effects observed on transcript, protein and metabolite levels.** *BMC Genomics* 2010, **11**:235.
27. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JAM: **Primer3Plus, an enhanced web interface to Primer3.** *Nucleic Acids Res* 2007, **35**:W71-W74.
28. Ramakers C, Ruijter JM, Deprez RHL, Moorman AFM: **Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data.** *Neuroscience Lett* 2003, **339**:62-66.
29. Pfaffl MW: **A new mathematical model for relative quantification in real-time PCR.** *Nucleic Acids Res* 2001, **29**:2002-2007.
30. Law PJ, Claudel-Renard C, Joubert F, Louw AI, Berger DK: **MADIBA: a web server toolkit for biological interpretation of *Plasmodium* and plant gene clusters.** *BMC Genomics* 2008, **9**:105.
31. Grass S, Zidorn C, Ellmerer EP, Stuppner H: **Eudesmane derivatives from *Hieracium intybaseum*.** *Chemistry and Biociversity* 2004, **1**:353-360.
32. Hasbun C, Calvo MA, Poveda LJ, Malcolm A, Delord TJ, Watkins SF, Fronczek FR, Fischer NH: **Molecular structure of irazunolide, a new eudesmanolide from *Hieracium irazuensis*.** *J Nat Prod* 1982, **45**:749-753.
33. Rademeyer M, Van Heeren FR, Van der Merwe MM: **Dehydrobrachylaenolide: an eudesmanolide-type sesquiterpene lactone.** *Acta Cryst* 2009, **E65**:o196.
34. Klayman DL: **Qinghaosu (artemisinin): an antimalarial drug from China.** *Science* 1985, **228**:1049-1055.
35. Bischoff TA, Kelley CJ, Karchesy Y, Laurantos M, Nguyen-Dinh P, Arefi AG: **Antimalarial activity of lactucin and lactucopicrin: sesquiterpene lactones isolated from *Cichorium intybus* L.** *J Ethnopharmacol* 2004, **95**:455-457.
36. Chea A, Hout S, Long C, Marcourt L, Faure R, Azas N, Elias R: **Antimalarial activity of sesquiterpene lactones from *Vernonia cinerea*.** *Chem Pharm Bull* 2006, **54**:1437-1439.
37. Pillay P, Vlegaar R, Maharaj VJ, Smith PJ, Lategan CA: **Isolation and identification of antiplasmodial sesquiterpene lactones from *Oncosiphon piluliferum*.** *J Ethnopharmacol* 2007, **112**:71-76.
38. Pink R, Hudson A, Mouries MA, Bendig M: **Opportunities and challenges in antiparasitic drug discovery.** *Nat Rev Drug Discov* 2005, **4**:727-740.
39. Lee K-H, Huan E-S, Piantadosi C, Pagano JS, Geissman TA: **Cytotoxicity of sesquiterpene lactones.** *Cancer Research* 1971, **31**:1649-1654.
40. Medjiroubi K, Benayache F, Bermejo J: **Sesquiterpene lactones from *Centaurea musimomum*. Antiplasmodial and cytotoxic activities.** *Fitoterapia* 2005, **76**:744-746.
41. Natalang O, Bischoff E, Deplaine G, Proux C, Dillies M-A, Sismeiro O, Guigon C, Bonnefoy S, Patarapotikul J, Mercereau-Puijalon O, Coppee J-Y, David PH: **Dynamic RNA profiling in *Plasmodium falciparum* synchronized blood stages exposed to lethal doses of artesunate.** *BMC Genomics* 2008, **9**:388.
42. Afolayan AJ, Sultana N: **Bioactive sesquiterpene lactones isolated from the shoots of *Arctotis arctotoides*.** *SA J Bot* 2003, **69**:158-160.
43. Francois G, Passreiter CM: **Pseudoguaianolide sesquiterpene lactones with high activities against the human malaria parasite *Plasmodium falciparum*.** *Phytother Res* 2004, **18**:184-186.
44. Van Brummelen AC, Olszewski KL, Wilinski D, Llinas M, Louw AI, Birkholtz L-M: **Co-inhibition of *Plasmodium falciparum* S-adenosylmethionine decarboxylase/ornithine decarboxylase reveals perturbation-specific compensatory mechanisms by transcriptome, proteome, and metabolome analyses.** *J Biol Chem* 2009, **284**:4635-4646.
45. Wang J, Huang L, Li J, Fan Q, Long Y, Li Y, Zhou B: **Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation.** *PLoS ONE* 2010, **5**:e9528.
46. Siedle B, Garcia-Piñeres AJ, Murillo R, Schulte-Mönting J, Castro V, Rüngeler P, Klaas CA, Da Costa FB, Kiesel W, Merfort I: **Quantitative structure-activity relationship of sesquiterpene lactone as inhibitors of the transcription factor NF- κ B.** *J Med Chem* 2004, **47**:6042-6054.
47. Hejchman E, Haugwitz RD, Cushman M: **Synthesis and cytotoxicity of water-soluble ambrosin prodrug candidates.** *J Med Chem* 1995, **38**:3407-3410.
48. Shaikenov TE, Adekenov SM, Williams RM, Prashad N, Baker FL, Madden TL, Newman R: **Araglabin-DMA, a plant-derived sesquiterpene, inhibits farnesyltransferase.** *Oncology Reports* 2001, **8**:173-179.
49. Bhonsle JB, Kamath HV, Nagasampagi BA, Ravindranathan T: **Secondary amine adducts of parthenin as potential antimalarial drugs.** *Indian J Chem Sect B* 1994, **33**:391-392.
50. Hwang DR, Wu YS, Chang CW, Lien TW, Chen WC, Tan UK, Hsu JTA, Hsieh HP: **Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system.** *Bioorg Med Chem* 2006, **14**:83-91.
51. Willuhn G: *Neue Ergebnisse der Arnikaforschung.* *Pharm Unserer Zeit* 1981, **10**:1-7.
52. Colombo MI, Testero SA, Pellegrinet SC, Bohn ML, Ruveda AE: **The dienone-phenol rearrangement of santonin: A comprehensive laboratory**

experiment for advanced undergraduate organic chemistry students.
Chem Educator 2001, **6**:350-352.

doi:10.1186/1475-2875-10-295

Cite this article as: Becker *et al.*: *In vitro* anti-plasmodial activity of *Dicoma anomala* subsp. *gerrardii* (Asteraceae): identification of its main active constituent, structure-activity relationship studies and gene expression profiling. *Malaria Journal* 2011 **10**:295.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

